IVF and Age Limits: Realistic Success Rates and Boundaries After 40

Key Takeaways

Age strongly shapes IVF with your own eggs. A live birth means a baby born alive — not only a positive pregnancy test. Treatment after 40 can still be discussed, but the chance falls with age and is not fixed by follicle count alone. Clear registry numbers, ovarian-reserve tests, and agreed stopping points make a safer decision.

Key evidence: SART — National Summary Report (2023 US Data) · ASRM — Testing and Interpreting Measures of Ovarian Reserve (2020) · ASRM — PGT-A Committee Opinion (2024)

Age is one of the strongest factors in IVF when you use your own eggs. ASRM’s ovarian-reserve opinion explains why AMH and follicle counts are not a stand-in for age.

Many women and couples in their 40s ask three practical questions. Is another cycle still reasonable? What is the chance of a live birth — a baby born alive, not only a positive test? When does another attempt stop making medical sense?

After 40, those answers need clear definitions, not a single clinic headline. Start with ovarian reserve, the age-related rise in chromosomal problems in eggs, how the clinic counts outcomes, and a plan for when to stop.

The Core Question: Is There a Strict Age Limit for IVF?

There is no single international age cut-off for every clinic. Success with a patient’s own eggs usually falls as age rises, with a sharper drop in the older bands.

Two separate biological changes drive that pattern. Chromosomal abnormalities become more common with age. The number of remaining follicles also falls. They affect different steps of IVF and cannot be reduced to one AMH value.

Ovarian Reserve vs. Egg Quality: The Vital Distinction

Does AMH tell us about egg quality? No.

AMH and antral follicle count (AFC) mainly help estimate how the ovaries may respond and how many eggs might be retrieved. Chromosomal competence — whether an embryo has the expected number of chromosomes — tracks age much more closely (ASRM’s ovarian-reserve opinion).

• Ovarian reserve (AMH and AFC): Useful for predicting egg yield. Weak as a stand-alone predictor of reproductive potential.
• Chromosomal competence: A higher AMH may give more eggs to work with. It does not guarantee a euploid embryo (one with the usual chromosome set) or reverse age-related changes in the eggs. Aneuploidy rates also vary by study design, laboratory, and the population examined (Franasiak et al., 2014).

A higher AMH at 43 or 44 may increase the number of eggs retrieved. It does not reverse the biological age of those eggs.

IVF Live Birth Rates by Age: What the Registries Show

Registry data beat a clinic headline — if the age band and the denominator are clear.

The 2023 SART national report reports live births per intended egg retrieval with the patient’s own eggs, including linked transfers in the follow-up window. That count also includes cycles that never reached transfer.

SART does not split the oldest group into 43–44 and 45+. It uses these published bands:

These are US national averages, not an individual forecast. They cannot give separate rates for 43–44 and 45+.

European ESHRE/EIM reports often use different endpoints (for example rates per transfer). Those figures cannot be lined up side by side with SART’s per-intended-retrieval rates. Always ask who was counted and what was measured.

High clinic percentages for women in their 40s may describe donor eggs, a cumulative rate, a biochemical pregnancy, or results after transfer of a selected euploid embryo. Ask for live birth per intended retrieval with the patient’s own eggs.

The Role and Limitations of PGT-A After 40

PGT-A (preimplantation genetic testing for aneuploidy) is often discussed later in reproductive life. It can estimate chromosome copy number in an embryo. It does not erase the biological limits of the eggs or guarantee a live birth.

• What PGT-A does: A few cells are taken from the outer layer of a day-5 or day-6 blastocyst. ASRM’s 2024 PGT-A opinion discusses retrospective work in women aged 40–43, including Lee et al. (2015), which reported an implantation rate of about 51% after transfer of a euploid embryo. That figure applies only once a euploid embryo is available. It is not a universal rate for every patient or laboratory.
• What PGT-A cannot do: It cannot correct an abnormal embryo or create a healthy one. It does not guarantee implantation, a pregnancy that continues, or live birth.
• When embryo numbers are low: Some patients over 42 have only one or two blastocysts. If all are reported as aneuploid, there may be nothing to transfer. Testing should weigh expected embryo numbers, laboratory practice, cost, and the patient’s goals.

With very few embryos, choose PGT-A or an unbiopsied fresh or frozen transfer with the treating physician.

Supplements such as CoQ10 or DHEA after 42

CoQ10 and DHEA have not been shown to restore age-related chromosomal competence or to raise live birth in a reliable way. ESHRE’s 2023 add-on recommendations do not support routine DHEA with stimulation. They also advise against routine antioxidant therapy in ART. That advice covers antioxidants as a group rather than a CoQ10-only verdict. Discuss indication, safety, and interactions with the treating clinician before starting either supplement.

Regulatory and Legal Context in Turkey

For international patients considering treatment in Türkiye, check the assisted-reproduction rules and health-tourism rules separately. ST-1008 names the clinic’s international health-tourism authorisation. It is not itself the rule for embryo transfer or gamete eligibility.

1. Own eggs and sperm: Under the Turkish assisted-reproduction framework, treatment uses the couple’s own eggs and sperm. Donor eggs, donor sperm, and surrogacy are not available in this framework.
2. Embryo-transfer numbers: The main text of the regulation linked above does not set an age-based limit on the number of embryos transferred. At Dr. Aksoy’s centre, one embryo is transferred under age 35, and two embryos from age 35 or after two unsuccessful attempts. Ask any centre how many embryos it would transfer in your case, and on what basis.
3. Upper-age question: The regulation text cited here does not state one simple upper-age ceiling for own-egg IVF. That does not mean treatment fits every age. Eligibility, medical safety, and informed consent still need assessment.

Dr. Aksoy’s Approach: Medical Realism and Setting Boundaries

At later reproductive ages, a useful consultation does two things. It states the limits honestly. It gives a clear way to decide whether to continue.

1. Review AMH, AFC, medical history, and prior stimulation response.
2. Discuss individualised chances in plain language, including uncertainty.
3. Agree a trial plan with stopping points before medicines start.
4. If follicles respond and a transferable blastocyst develops, plan transfer when appropriate.
5. If there is no response, or no euploid or transferable embryo after repeated attempts, stop and discuss other options.

I focus on agreeing the stopping points before stimulation begins:

• Before medication: We review AMH, antral follicle count, history, and previous response. When the individualised estimate is very low, we say what that means — and what it still cannot predict.
• Very low AMH at 41–43: A very low AMH does not make pregnancy impossible, but I tell the patient at the outset that the chance of success is quite limited. Two problems combine: lower ovarian reserve means fewer eggs, and age lowers the chance that those eggs become chromosomally healthy embryos — more clearly at 43. I do not decide on AMH alone. I also look at the follicles I see on ultrasound, whether periods continue, and the eggs and embryos from earlier cycles. If follicles that can develop are present, I may consider a trial with her own eggs after a realistic conversation about expectations. If repeated stimulation yields no eggs, or embryos keep stopping development, I do not recommend repeating the same treatment. I aim to give no false hope, yet not to close every option on low AMH alone.
• Good AMH or follicle count after 42: Favourable AMH and antral follicle count results can influence my decision, because those patients may respond better to stimulation and yield more eggs. These results tell us about egg numbers, not chromosomal quality: a 43-year-old with a high AMH still has 43-year-old eggs. I treat good ovarian reserve as a favourable finding, but I do not regard it as cancelling the effect of age. After 42, even when reserve looks good, I base the live-birth discussion on age and, when available, on how embryos developed in earlier cycles.
• If the patient chooses a trial: The plan should state how many attempts are reasonable and which findings would change course. Stimulation is individualised. No protocol reverses age-related chromosomal changes.
• When to stop: No follicular response, poor fertilisation, or repeated failure to develop a transferable embryo may be reasons to reconsider another cycle. Repeating the same approach without a new rationale can add physical, emotional, and financial burden.
• Maternal health: Pregnancy after 40 is linked with higher risks of hypertension, preeclampsia, gestational diabetes, and caesarean birth. Pre-conception assessment should include cardiovascular and metabolic health. ACOG guidance

Frequently Asked Questions for Dr. Aksoy

Is there an upper age limit for IVF with your own eggs in Turkey, and when do you not recommend treatment at 43–45?

Turkey does not set one fixed upper age limit for IVF that applies to every patient. I also do not decide on treatment from age alone. After 43–44, however, the chance of live birth with a patient’s own eggs falls sharply, and at 45 that chance is much lower still.

At these ages I look first at ovarian reserve, the follicles I see on ultrasound, and — when available — the eggs and embryos from earlier cycles. If earlier, appropriate stimulation still yielded very few eggs, or no transferable embryo developed, I discuss openly with the patient whether another attempt is likely to offer a meaningful chance.

What decides it for me is not a rigid age cut-off, but whether we can still offer a realistic chance of pregnancy. When the chance of success is extremely low, I do not think it is right to steer a patient toward unnecessary treatment.

Is live birth with your own eggs still possible at 45?

Yes, in theory it is possible. I tell patients clearly, though, that in practice it is very uncommon. At 45 the main problem is not only fewer eggs: the chance of chromosomal abnormalities in the eggs rises sharply.

Sometimes we can retrieve eggs and even develop embryos that look good. That does not mean those embryos are chromosomally normal. Even if a pregnancy begins, the risk of miscarriage is also higher.

I do not tell a 45-year-old patient that pregnancy is impossible, and I also do not present a very low probability as a realistic expectation of success. If we decide to treat, we do so after weighing the likely outcomes and the health risks of pregnancy together.

Sources

• Practice Committee of the American Society for Reproductive Medicine. “Testing and interpreting measures of ovarian reserve: a committee opinion.” Fertility and Sterility 114.6 (2020): 1151-1157. ASRM ovarian reserve 2020
• Society for Assisted Reproductive Technology (SART). “National Summary Report (2023 Data).” SART 2023
• European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). “ART in Europe, 2019: results generated from European registries by ESHRE.” Human Reproduction 38.12 (2023): 2321-2338. ESHRE/EIM 2019
• Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. “The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion.” Fertility and Sterility 122.3 (2024): 421-434. ASRM PGT-A 2024 · DOI: 10.1016/j.fertnstert.2024.04.013
• Lee HL, McCulloh DH, Hodes-Wertz B, Adler A, McCaffrey C, Grifo JA. “In vitro fertilization with preimplantation genetic screening improves implantation and live birth in women age 40 through 43.” Journal of Assisted Reproduction and Genetics 32.3 (2015): 435-444. PubMed
• Franasiak JM, Forman EJ, Hong KH, et al. “The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening.” Fertility and Sterility 101.3 (2014): 656-663. PubMed
• ESHRE Add-ons working group; Lundin K, Bentzen JG, Bozdag G, et al. “Good practice recommendations on add-ons in reproductive medicine.” Human Reproduction 38.11 (2023): 2062-2104. PMC · DOI: 10.1093/humrep/dead184
• American College of Obstetricians and Gynecologists. “Pregnancy at Age 35 Years or Older.” (2022). ACOG
• Republic of Türkiye, Ministry of Health. “Assisted Reproduction Treatment Practices and Centres Regulation.” Mevzuat

Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed · ORCID · LinkedIn

Read full profile → Instagram YouTube

The content has been created by Dr. Senai Aksoy and medically approved.